We are contrasting Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC) on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Osmotica Pharmaceuticals plc	274.34M	1.38	6.40M	-0.13	0.00
ImmunoCellular Therapeutics Ltd.	N/A	0.00	9.03M	-0.48	0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Osmotica Pharmaceuticals plc and ImmunoCellular Therapeutics Ltd.

Profitability

Table 2 represents Osmotica Pharmaceuticals plc (NASDAQ:OSMT) and ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC)’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Osmotica Pharmaceuticals plc	-2.33%	0%	0%
ImmunoCellular Therapeutics Ltd.	0.00%	-321.9%	-158.6%

Liquidity

The Current Ratio and a Quick Ratio of Osmotica Pharmaceuticals plc are 1.3 and 1.1. Competitively, ImmunoCellular Therapeutics Ltd. has 9.5 and 9.5 for Current and Quick Ratio. ImmunoCellular Therapeutics Ltd.’s better ability to pay short and long-term obligations than Osmotica Pharmaceuticals plc.

Institutional and Insider Ownership

Institutional investors owned 37% of Osmotica Pharmaceuticals plc shares and 4.3% of ImmunoCellular Therapeutics Ltd. shares. About 41.8% of Osmotica Pharmaceuticals plc’s share are owned by insiders. On the other hand, insiders owned about 0.3% of ImmunoCellular Therapeutics Ltd.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Osmotica Pharmaceuticals plc	-0.38%	-11%	0%	0%	0%	-3.68%
ImmunoCellular Therapeutics Ltd.	1.08%	-26.32%	-88.09%	-88.69%	-90.34%	-91.14%

For the past year Osmotica Pharmaceuticals plc’s stock price has smaller decline than ImmunoCellular Therapeutics Ltd.

Summary

Osmotica Pharmaceuticals plc beats ImmunoCellular Therapeutics Ltd. on 7 of the 9 factors.

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER to treat Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone to treat muscle spasms; and ConZip for pain, as well as women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. Its non-promoted approved products comprise Methylphenidate ER for ADHD; Venlafaxine ER tablets for major depressive disorder and social anxiety disorder; Hydromorphone ER for pain; Nifedipine ER for hypertension; Sodium Benzoate/Sodium Phenylacetate for hyperammonemia; Oxybutynin ER for overactive bladder; and prescription prenatal vitamins for nutritional requirements during pregnancy. The company's products under development include Ontinua ER, which is in Phase III clinical trials to treat multiple sclerosis spasticity, and Phase I clinical trials to treat opioid and alcohol use disorders; RVL-1201, which is in Phase III clinical trials to treat Blepharoptosis; and Osmodex and other ANDAs for various indications. Osmotica Pharmaceuticals plc is based in Bridgewater, New Jersey.

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.